<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03206957</url>
  </required_header>
  <id_info>
    <org_study_id>P2017/Ophtalmo/DOPANUR</org_study_id>
    <nct_id>NCT03206957</nct_id>
  </id_info>
  <brief_title>Correlation Between Optic Nerve Vessel Anomalies, Serum Angiogenic Factors and Renal Anomalies in Down Syndrome Children</brief_title>
  <acronym>DOPANUR</acronym>
  <official_title>Interventional Controlled Cross-sectional Study Assessing the Correlation Between Optic Nerve Vessels Anomalies, Serum Angiogenic Factors and Renal Anomalies in Children With Down Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Fabiola Children's University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen Fabiola Children's University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In approximately half of individuals with Down syndrome, an higher than normal number of&#xD;
      vessels cross the optic disc margin. Investigator hypothesize that early retinal vessel&#xD;
      branching occurs due to inhibition of angiogenesis by triplet overexpression of endostatin,&#xD;
      an angiogenesis inhibitor encoded on chromosome 21. Since angiogenesis is critical in the&#xD;
      development of eyes and other organs angiogenesis depended (specially kidney, brain, and&#xD;
      recently described lungs and heart), early branching of retinal vessels at the level of the&#xD;
      optic disc would also likely result in abnormal renal and other organs development in these&#xD;
      individuals. Investigator wish to determine whether observation of optic disc vessels may&#xD;
      serve as an indicator of elevated endostatin levels and other angiogenesis-dependent organs&#xD;
      anomalies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigator will measure the serum levels of endostatin as well as others angiogenetic&#xD;
      factors in Down syndrome children versus control group 1 constituted by the patient mothers.&#xD;
&#xD;
      Investigator will also perform renal and low urinary tract Doppler ultrasound with&#xD;
      measurement of renal dimension in order to determine if the kidneys of patients with high&#xD;
      level of serum of endostatin are smaller than those of patients with normal level of&#xD;
      endostatin. Data observed in Down syndrome children will be compared to control group 2age&#xD;
      constituted by sex and age matched healthy children Urine microalbuminuria and urine&#xD;
      microalbuminuria/creatinuria from the first urine in the morning will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Interventional controlled cross-sectional study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between the number of retinal vessels crossing the optic disc and serum level of endostatin</measure>
    <time_frame>18 months</time_frame>
    <description>correlation coefficent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between the number of retinal vessels crossing the optic disc and serum level of other angiogenic factors</measure>
    <time_frame>18 months</time_frame>
    <description>correlation coefficent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between serum level of endostatin and serum level of other angiogenic factors</measure>
    <time_frame>18 months</time_frame>
    <description>correlation coefficient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of renal anomalies in Down syndrome.</measure>
    <time_frame>18 months</time_frame>
    <description>absolute number and type of renal anomalies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of prevalence of renal anomalies between Down syndrome and healthy subjects</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion and type of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the number of optic nerve vessels and the presence of organs pathologies</measure>
    <time_frame>18 months</time_frame>
    <description>correlation coefficient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between serum level of angiogenesis factors and the presence of organs pathologies</measure>
    <time_frame>18 months</time_frame>
    <description>correlation coefficient</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Down Syndrome</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Down Syndrome children</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group n°1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Down Syndrome children's mothers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group n°2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Age and sex matched healthy children</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group n°3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Down syndrome children's healthy siblings</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Funduscopic examination and retinal photography</intervention_name>
    <description>A standardized funduscopic examination and retinal photography will be performed by an ophthalmologist focusing on optic nerve.</description>
    <arm_group_label>Control group n°1</arm_group_label>
    <arm_group_label>Control group n°2</arm_group_label>
    <arm_group_label>Control group n°3</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serum levels of endostatin and angiogenesis factors</intervention_name>
    <description>Serum levels of endostatin, angiopoietin and vaso endothelial growth factor will be analyzed</description>
    <arm_group_label>Control group n°1</arm_group_label>
    <arm_group_label>Control group n°3</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Renal and low urinary tract Doppler ultrasound</intervention_name>
    <description>Measurements of each kidney will include maximum renal bipolar length in a sagittal plane, renal width and thickness in an axial plane perpendicular to each other at the level of renal hilum and cortical thickness. Intensity of corticomedullary differentiation will estimated.&#xD;
Doppler ultrasound examination will assess renal arterial resistivity indexes</description>
    <arm_group_label>Control group n°2</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Urinalysis</intervention_name>
    <description>Urinalysis assessments will include assessments of microalbuminuria and microalbuminuria to creatinuria ratio. A spot urine sample will be collected from first morning void.</description>
    <arm_group_label>Control group n°2</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Anthropometric measures and vitals signs</intervention_name>
    <description>weight, height and blood pressure will be assessed</description>
    <arm_group_label>Control group n°2</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of personally signed and dated informed consent document by adult subject or&#xD;
             parents&#xD;
&#xD;
          -  When capable of providing assent, provision of personally signed and dated informed&#xD;
             assent document by children&#xD;
&#xD;
          -  Subjects and/or their caregivers/parents are willing and able to comply with scheduled&#xD;
             laboratory tests, and other required study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Inability to cooperate with study related examination&#xD;
&#xD;
        For &quot;Study Group&quot; subjects&#xD;
&#xD;
          -  Known chronic diseases unrelated to their triallelic condition For &quot;Control Group n°1&quot;&#xD;
             &amp; &quot;Control Group n°3&quot;&#xD;
&#xD;
          -  General disease in which the level of endostatin may be modified such as leukemia,&#xD;
             cancers, inflammatory diseases (e.g.: rheumatoid arthritis, Crohn's disease,&#xD;
             psoriasis)&#xD;
&#xD;
          -  Any condition that may cause a hypoxia&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
        For &quot;Control Group n°2&quot;:&#xD;
&#xD;
          -  Healthy children except benign ophthalmological refraction anomalies&#xD;
&#xD;
          -  Any known renal or low urinary tract diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lavina Postolache, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Fabiola Children's University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lavina Postolache, MD</last_name>
    <phone>0032 2 477 21 92</phone>
    <email>lavina.postolache@huderf.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Universitaire Des Enfants Reine Fabiola</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lavina Postolache, MD</last_name>
      <phone>0032 2 477 21 92</phone>
      <email>lavina.postolache@huderf.be</email>
    </contact>
    <investigator>
      <last_name>Lavina Postolache, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>June 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>July 3, 2018</last_update_submitted>
  <last_update_submitted_qc>July 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endostatins</mesh_term>
    <mesh_term>Angiogenesis Inducing Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

